Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
ANEXSIA vs PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Propoxyphene is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates central pain pathways.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
One tablet (propoxyphene HCl 65 mg/acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum: 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Propoxyphene: 6-12 h (prolonged in hepatic disease); Norpropoxyphene (active metabolite): 30-36 h (accumulation risk). Acetaminophen: 2-3 h (prolonged in hepatic disease).
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Renal: Propoxyphene ~20-25% as unchanged drug and metabolites; Acetaminophen ~85-90% as glucuronide and sulfate conjugates, <5% unchanged. Fecal: Minimal for both.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination